Notícias

RapAdmin

A 35-year longitudinal cohort study from Norway reveals that individuals reporting mental health impairments in their 30s and 40s experience significantly higher levels of physical frailty after age 70. Using two distinct frailty models, researchers found that early midlife psychological distress nearly doubles the relative risk of becoming physically frail in older adulthood. These findings underscore the necessity of treating mental health as a core component of biological aging and longevity optimization, rather than a separate psychological phenomenon.

Psychological health is inextricably linked to physical durability. The HUNT study tracked over 27,000 Norwegians for more than three decades to determine if self-reported mental health impairment in midlife accelerates the accumulation of physical deficits in later life. The data reveals that psychological distress is not merely a transient emotional state but a physiological exposure that accelerates the deterioration of multiple somatic systems. By evaluating individuals through both the Fried physical frailty phenotype and the 35-item HUNT4 Frailty Index, the researchers demonstrate a persistent structural decline in physical capacity.

The biological toll observed in this study likely represents an underestimation (i.e. things are even worse than they are presented). The data exhibits a massive survivor bias. Mortality prior to the follow-up assessment at age 70 was 55.5 percent for individuals who reported early midlife mental health problems, compared to only 36.6 percent for those who did not. This indicates that the participants with a history of mental health challenges who survived to be tested at age 70 represent only the most robust fraction of that initial cohort. Even within this resilient subset, the differences in physical deterioration were profound.

Mental health impairment in early midlife drives a systemic erosion of physical reserves that is detectable over 35 years later. The associations remained robust even after adjusting for traditional lifestyle confounders like physical activity, obesity, smoking, and alcohol consumption. This strongly suggests that psychological distress exerts direct pathogenic effects on physical aging independent of behavioral coping mechanisms. Clinicians and researchers focused on lifespan extension must integrate proactive psychological monitoring and interventions into standard physiological health protocols. Treating depression, chronic stress, and anxiety is a structural necessity for maintaining late-life musculoskeletal and functional independence.

Actionable Insights

Midlife mental health impairment exerts a biological cost equivalent to decades of accelerated aging. For adults aged 35 to 49, reporting psychological distress resulted in an absolute increase of 0.066 on the Frailty Index by age 70. Because the Frailty Index typically increases by approximately 0.03 per decade in older adults, this 0.066 penalty is roughly equivalent to two additional decades of biological deficit accumulation.

The practical outcome is a severe loss of functional independence. At age 70, the prevalence of being categorized as physically “robust” dropped from 51 percent in the unexposed group to only 25.7 percent in the group with prior mental health problems. The prevalence of overt frailty doubled from 8.9 percent to 18.5 percent.

To optimize longevity, psychological stress and mental health disorders must be treated with the same aggressive intervention strategies used for hyperlipidemia or insulin resistance. Relying solely on physical exercise and diet is insufficient if the central nervous system remains in a state of chronic distress. Implementing cognitive behavioral therapy, prioritizing stress management protocols, and seeking psychiatric care are mandatory steps to prevent accelerated sarcopenia and loss of mobility in later life.

Context/Source

  • Open Access Paper: Midlife mental health and frailty up to 35 years later: Insights from the HUNT study
  • Institution: The Norwegian National Centre for Ageing and Health, Vestfold Hospital Trust, University of Oslo
  • Country: Norway
  • Journal: Archives of Gerontology and Geriatrics
  • Impact Evaluation: The impact score of this journal is 4.0, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

Researchers recorded 2,928 Spanish speakers in five Latin American countries and trained a model to guess each person’s age from how they spoke. The difference between guessed and real age, called the speech age gap (SAG), was larger in people with Alzheimer’s disease and frontotemporal dementia than in healthy volunteers. It tracked moderately with MRI-based brain age and weakly with plasma p-Tau217, three DNA methylation clocks and social disadvantage. The model misses true age by about 9 years on average. It is a research instrument, not a screening test.

Aging clocks estimate how old a body looks compared with its birth certificate. Most need blood or a brain scan, which keeps them out of the low-income regions where dementia is rising fastest. A consortium led from the Latin American Brain Health Institute in Chile asked whether a few minutes of recorded speech could do a similar job.

The logic is reasonable. Speaking draws on memory, attention, emotion and fine motor control at the same moment. Slower speech, longer pauses, flatter pitch and vaguer word choice are all known features of aging and dementia.

Participants narrated a short film, named animals and vegetables against the clock, listed words beginning with a set letter, and retold a short story twice. Software extracted more than 700 measurements and condensed them into seven scores covering timing, pitch, emotional tone, word choice and verbosity. A machine-learning model then predicted each person’s age.

As a clock, it is loose. The model explained 44 percent of the variation in age and missed by 9 years on average, in a cohort where most people were between about 54 and 76.

The gap still separated groups. Take one healthy volunteer and one patient at random, and the patient had the older-sounding speech between two-thirds and nearly nine-tenths of the time, depending on diagnosis. Language-dominant frontotemporal dementia, which attacks language directly, showed the largest gaps. The pattern held after matching for age, sex and education.

The most persuasive check came from MRI. Speech age gap explained roughly a fifth to a quarter of the variation in brain age gap, including within healthy volunteers. Links to the blood tau marker and to epigenetic clocks were far weaker, at about 4 percent of variation.

Three problems limit what can be concluded. First, the story-retelling task feeds both the speech clock and the memory score it is validated against. Someone who recalls less says less, so part of that correlation is one performance counted twice.

Second, education shaped the speech features more than any other background factor, and in healthy volunteers larger gaps tracked social disadvantage. Older-sounding speech may partly reflect fewer years of schooling instead of faster biological aging.

Third, the promise of cheap, scalable testing was not tested. Recordings were made in quiet rooms by neuropsychologists using studio-grade recorders, and transcripts were corrected by hand. Nothing was collected remotely, in conversation, or in another language.

There is also an undeclared interest. The paper states no competing interests, yet a corresponding author created the speech-analysis toolkit used here, which operates as an investor-backed startup.

Speech carries a signal that differs in dementia and echoes brain imaging. Whether it predicts anyone’s future remains unknown.

Actionable Insights

No intervention was tested, so it cannot say whether exercise, diet, drugs or cognitive training would change a speech age gap, or whether changing it would matter.

The size of the effects explains why. The model’s average error was 9 years, which is larger than the typical difference it found between patients and healthy people. A single person’s reading is therefore uninformative. At the group level, a patient sounded older than a healthy volunteer 66 to 88 percent of the time, where 50 percent would be a coin flip. That is a real difference between groups, but the paper gives no false-positive or false-negative rates, so its value for screening is unknown.

The agreement with blood markers was small. Speech gap explained about 4 percent of the variation in p-Tau217 and in epigenetic age, and 18 to 28 percent of MRI brain age gap.

Practical points:

  • Be skeptical of any app offering a “voice age” on the strength of this study.
  • Speaking more languages was not shown to help. The association was tiny and not statistically significant.
  • A noticeable change in word-finding or fluency deserves a clinical evaluation. That advice predates this paper.

Context and Source

  • Open Access Paper: Speech clocks decode dementia phenotypes, social exposome, and biological aging
  • Lead institutions: Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Chile; Cognitive Neuroscience Center, Universidad de San Andrés, Argentina
  • Journal: Science Advances (AAAS), published 30 September 2026
  • Impact evaluation: The impact score of this journal is 13.9 (Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

Researchers led from the MRC Laboratory of Medical Sciences in London tested compound 991, a drug that binds and activates the energy-sensing enzyme AMPK directly, in fission yeast, nematode worms and fruit flies. All three lived longer at the right dose, and the benefit vanished in yeast and worms lacking AMPK. They gave nanoparticle-packaged 991 by injection for three weeks and reported liver protein changes they describe as pro-longevity. The work is a clean proof of principle for AMPK as a drug target in invertebrates and an invitation to run mouse lifespan studies.

For two decades, AMPK has been one of the most talked-about targets in aging biology. The enzyme works like a cellular fuel gauge: when energy runs low, it switches on fat burning and recycling programs and dials down costly growth. Animals engineered to have more active AMPK tend to live longer. The trouble has been proving that a drug can do the same thing.

Metformin, the usual stand-in, is a poor test. It activates AMPK only indirectly, by mildly stressing mitochondria, and it hits many other targets. In worms and flies, its lifespan effects even run through gut bacteria rather than the animal itself. So a positive metformin result says little about AMPK, and a negative one says little either.

The new study in Aging Cell takes the direct route. Compound 991 slots into a pocket on the AMPK protein itself and turns the enzyme on. The team first showed that this pocket is conserved from humans down to yeast, and that 991 activates fly and worm AMPK at concentrations roughly a thousand times lower than metformin requires.

Then came the survival experiments. Female fruit flies fed a low dose lived about 9 percent longer at the median. Worms lived roughly 18 to 20 percent longer on two different bacterial diets, which argues against a microbiome explanation. Fission yeast cultures also survived longer. Flies and worms carried less fat, and flies ate just as much as untreated animals, so this was not accidental dieting.

The most persuasive experiment is the genetic control. In yeast and worms with the AMPK gene deleted, 991 did nothing for lifespan. That is strong evidence the drug works through its intended target.

The mouse section is the weakest part. Three mice per group received intravenous nanoparticles for three weeks, and their liver proteins shifted in ways consistent with AMPK activation: more mitochondrial machinery, less general protein synthesis. The authors call this a pro-longevity signature. No mouse lived a day longer in this study, because lifespan was not measured.

There is also a safety question the paper leaves largely unaddressed. A related, more drug-like AMPK activator from Merck caused heart enlargement in rodents and monkeys. Chronic, whole-body AMPK activation may not be benign, so a pulsatile approach may be necessary.

The bottom line: this is the cleanest pharmacological evidence so far that turning on AMPK itself can extend life in simple organisms. Whether that holds in a mammal remains untested.

Actionable Insights

Compound 991 is a laboratory tool with poor absorption in mammals and known toxicity, which is why the mouse work needed nanoparticle packaging and injections.

The real-world magnitude was modest. In flies, the best dose added about 7 days to a 76-day median lifespan, roughly 9 percent. In worms, about 2.5 to 3 days on a 14-day median, roughly 18 to 20 percent. These figures cannot be converted into human years. Most interventions that work in worms and flies shrink or disappear in mice.

Three practical lessons do carry over:

  1. More is not better. The dose that helped flies most was the lowest tested for lifespan. Higher doses helped less, then harmed. Anyone stacking multiple AMPK-activating compounds should take that seriously.
  2. This paper does not validate metformin or berberine for longevity. Its premise is that indirect activators are too messy to interpret.
  3. Exercise and periods without food remain the only well-established, low-risk ways to activate AMPK in humans.

Watch for mouse lifespan trials of second-generation direct activators.

Context and Source

  • Open Access Paper: Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies
  • Lead institutions: MRC Laboratory of Medical Sciences and Imperial College London, United Kingdom
  • Collaborating institutions: University of Cologne (CECAD and CMMC), Germany; Queen Mary University of London and The Francis Crick Institute, United Kingdom; Universite Claude Bernard Lyon 1, France
  • Journal: Aging Cell (Wiley, for the Anatomical Society), 2026
  • Impact evaluation: The impact score of this journal is 7.1 (Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

This narrative review from Kunming argues that type 2 diabetes behaves like accelerated aging and asks whether eight classes of glucose-lowering drugs could slow aging itself. Metformin has the broadest mechanistic evidence, SGLT-2 inhibitors and GLP-1 receptor agonists have the best human outcome data, and acarbose has the most reproducible mouse lifespan data.

For two decades, metformin has been the poster child of the idea that a cheap diabetes pill might slow aging. A new review in Pharmacological Research widens the lens to every major class of glucose-lowering drug and asks which, if any, deserve the label “geroprotector.”

The starting premise is that type 2 diabetes looks like aging on fast-forward. People with diabetes show shorter telomeres, more senescent cells, more chronic inflammation and failing mitochondria. In UK Biobank imaging data, diabetic brains appeared about two years older than expected. Muscle is lost roughly 40 percent faster. If high glucose and high insulin drive the same damage pathways as aging, drugs that relieve that pressure might slow aging more broadly.

The review then ranks the candidates. Metformin has the widest mechanistic footprint, touching AMPK, mTOR, autophagy, inflammation and the gut microbiome, plus one eye-catching monkey study. SGLT-2 inhibitors such as empagliflozin and dapagliflozin bring proven heart and kidney protection and mimic some features of fasting. GLP-1 drugs such as semaglutide reduce inflammation and may protect the brain. Acarbose, an old drug that blunts the glucose spike after starchy meals, has the most reproducible lifespan extension in mice.

The human trial section is where the data has lagged. In a randomized trial of older adults with frailty or sarcopenia, metformin did not improve walking speed, grip strength or frailty, and many participants tolerated it poorly. Another trial found metformin blunted the mitochondrial gains older adults normally get from aerobic exercise. For dementia, observational data and pooled trial data hint at 33 to 45 percent lower risk with GLP-1 drugs and SGLT-2 inhibitors in people with diabetes.

The authors’ own conclusion is, despite strong pre-clinical support, translational relevance remains uncertain due to model heterogeneity, limited randomized clinical evidence, and insufficient long-term follow-up. Clarifying tissue specificity, timing, dose, and patient selection will be essential for determining whether anti-diabetic agents can be safely repurposed as gerotherapeutics.

Actionable Insights

  1. Keep glucose in check. This is the best-supported lever. In UK Biobank data cited by the review, diabetes was linked to a brain that looked about 2.0 years older, versus 0.2 years for prediabetes, and a healthy lifestyle shrank the gap. Newly diagnosed diabetes was tied to 68 percent faster cognitive decline over four years.
  2. Protect muscle. People with diabetes lost about 0.24 kg of muscle per year versus roughly 0.17 kg in non-diabetics. That works out to about 1.1 kg of extra loss over 16 years.
  3. Do not assume metformin helps healthy older adults. The MET-PREVENT trial showed no functional benefit, and a separate trial showed blunted exercise adaptations.
  4. If you have diabetes, the choice of drug may matter for the brain. GLP-1 drugs were associated with 45 percent lower odds of dementia in pooled trials, and SGLT-2 inhibitors with a 43 percent lower rate in observational data. These are relative figures. Absolute benefits are probably much smaller, and the data are indirect.
  5. Dapagliflozin’s heart failure benefit is real even without diabetes. In DAPA-HF, as I recall the published result, about 5 fewer patients per 100 had an event over 18 months.
  6. Acarbose’s mouse data are interesting. See more here: Acarbose - Details On Another Top Anti-Aging Drug

Context and Source

  • Open Access Paper: Geroprotective potential of anti-diabetic medications: Bridging type 2 diabetes and accelerated aging, Sept. 2026
  • Institutions: Second Affiliated Hospital of Dali University (Third People’s Hospital of Yunnan Province), and the Kunming Institute of Zoology, Chinese Academy of Sciences
  • Country: China
  • Journal: Pharmacological Research, online 8 September 2026
    Impact evaluation: The impact score of this journal is approximately 10.8, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

Four cardiologists at Saint Luke’s Mid America Heart Institute argue that SGLT inhibitors (dapagliflozin, empagliflozin and relatives) are the most credible geroprotector now available, ahead of rapamycin and metformin. They pool 13 placebo-controlled outcome trials covering 90,413 patients and find a 12% relative reduction in death from any cause and a 10% reduction in first hospitalization. They then add mouse lifespan data, genetic studies and proposed fasting-mimicking mechanisms.

For a decade, SGLT inhibitors have been the quiet success story of cardiology. Designed to lower blood sugar by making the kidneys dump glucose into urine, they turned out to keep heart failure patients out of hospital and slow kidney decline, whether or not the patient had diabetes. A new review asks whether the class is doing something more basic: slowing aging itself.

The argument runs like this. Blocking the SGLT2 transporter sends 60 to 80 grams of glucose a day out in the urine, around 240 to 320 calories. Insulin falls, glucagon rises, and blood ketones climb from about 0.1 to 0.3 to 0.6 millimoles per liter. The body, the authors propose, reads this as mild fasting. In animal and cell experiments that state activates the energy sensor AMPK, quiets the growth pathway mTOR and increases autophagy, the cell’s recycling system. These are the same pathways targeted by calorie restriction and rapamycin.

What separates this class from other longevity candidates is human outcome data. Pooling 13 large trials, the authors calculate a hazard ratio for death of 0.88. In their model, 9.6% of placebo patients died within three years against 8.5% on the drug. First hospitalization for any reason fell from 29.8% to 27.2%. They also cite a genetic study in which people who carry variants that mimic lifelong SGLT2 inhibition had 22% lower all-cause mortality, and a National Institute on Aging mouse study in which canagliflozin extended median lifespan by 14% in males.

There are large caveats. Every trial participant was already ill, with an average risk of death many times that of a healthy 50-year-old. Preventing deaths in people with failing hearts and kidneys is what a good cardiorenal drug does, and it is not the same as slowing aging. The benefit in heart failure appears within weeks, which is far too quick for any change in the rate of aging and points instead to effects on fluid balance and cardiac workload. The mouse result held only in males, and a later study from the same program found that female mice started on the drug in midlife died sooner.

The paper is also a narrative review, not a systematic one. It appears in the first issue of a brand-new journal that does not yet have an impact factor or confirmed indexing. Its scorecard ranking SGLT inhibitors above rapamycin and metformin was graded by the authors themselves.

Insights

Assuming the same 12% relative benefit carries over (unproven), a 50-year-old with a yearly death risk near 0.4% would see about 700 people treated for three years to prevent one death. By comparison, genital yeast infections occur in roughly 6 in 100 women and 2 in 100 men.

Practical points from the paper:

  • The dose used for heart and kidney benefit is 10 mg daily of dapagliflozin or empagliflozin.
  • Generic dapagliflozin now costs about $25 to $55 for 90 days in the US.
  • Stop the drug during prolonged fasting, very-low-carbohydrate dieting, heavy drinking, severe illness and before surgery, because of the risk of ketoacidosis. This matters for anyone combining it with fasting or keto protocols.
  • Canagliflozin is the SGLT2 inhibitor with the best mouse lifespan data.

Context/Source

Leitura Relacionada:

RapAdmin

A retrospective analysis of US electronic health records compared about 417,000 adults aged 50 and over who had a diagnosed voice disorder with matched adults who had a routine check-up. Those with a voice disorder were 29 percent more likely to later be diagnosed with mild cognitive impairment, Alzheimer’s disease or dementia. The figure was 58 percent for voice disorders without hearing loss and roughly double for voice disorders with hearing loss. The authors argue voice disorders may be a stronger early marker than hearing loss. The data are observational, absolute risks are small, and the paper does not test whether treating the voice changes anything.

Hearing loss has spent the past decade as the headline modifiable risk factor for dementia. A team at Drexel University College of Medicine in Philadelphia now proposes that the other half of conversation, the voice, deserves similar attention.

Using TriNetX, a platform that pools anonymized records from US health systems, the researchers identified adults aged 50 and over who received a first diagnosis of dysphonia, aphonia or a related voice disorder between 2016 and 2026. Each was paired with a similar person whose index visit was a general medical exam. Pairs were matched on age, sex, race, ethnicity and six cardiovascular risk factors. Anyone with existing dementia, Parkinson’s disease, stroke, multiple sclerosis or ALS was excluded, and the first year after diagnosis was ignored to reduce the chance that the voice problem was simply an early symptom of something already underway.

Across 833,417 people, a voice disorder was associated with a 29 percent higher rate of later cognitive diagnoses. Hearing loss, run through the same pipeline in 3.3 million people, came out at 27 percent. When the voice group was split, people with a voice disorder and no recorded hearing loss had a 58 percent higher rate than their controls, and those with both conditions had roughly twice the rate.

The authors offer two explanations. The first is that the voice is an early casualty of brain disease. In Parkinson’s disease, abnormal protein deposits appear in the brainstem nuclei of the vagus nerve, which controls the larynx, years before tremor begins. The second is social. People who struggle to be heard may withdraw from conversation, and reduced social engagement is itself linked to dementia.

The appeal is practical. Voice diagnoses already sit in medical records, so no new test is needed to find these patients.

The caveats are substantial. The paper reports no event counts. Its survival curves suggest that only about 1.5 percent of controls received a cognitive diagnosis over ten years, far below what population studies find at this age, which implies many cases were never coded. In that setting, people who see more specialists are more likely to have a memory problem noticed and recorded. The matching ignored education, depression, alcohol, reflux, lung disease and how often people visit doctors.

The claim that voice beats hearing loss rests on subgroups compared against different control populations. The paper’s own forest plot appears to show no significant difference between the full voice cohort and the hearing loss cohort.

The finding is a plausible, hypothesis-generating signal that a persistent voice change in later life may travel with elevated neurological risk. It is not evidence that voice problems cause dementia, or that voice therapy prevents it.

Actionable Insights

  1. Persistent hoarseness deserves a medical look regardless of this paper. Existing ENT guidance recommends examining the larynx when a voice change lasts beyond about four weeks, mainly to rule out cancer, nerve injury and neurological disease.
  2. Keep the size of the risk in proportion. Relative increases of 29 to 104 percent sound large, but the baseline is low. If about 15 in 1,000 matched controls received a cognitive diagnosis over ten years (my reading of the paper’s curves), then a voice disorder corresponds to roughly 19 in 1,000, voice disorder without hearing loss to about 24, and voice plus hearing loss to about 30. That is 4 to 15 extra diagnoses per 1,000 people over a decade. Converted to a standardized scale, these are small effects (Cohen’s d of roughly 0.14 to 0.39, where 0.2 is conventionally “small”).
  3. There is no evidence here that voice therapy protects the brain. The study did not examine treatment.
  4. Use a late-life voice change as a prompt to check better-supported dementia risk factors: hearing, blood pressure, LDL cholesterol, diabetes, physical activity and social contact.
  5. If you have both a voice disorder and hearing loss, a baseline cognitive screen is a reasonable, low-cost conversation to have with a clinician.

Context/Source

  • Open Access Paper: Voice Disorders as Early Biomarkers of Cognitive Decline
  • Institution: Drexel University College of Medicine, Department of Otolaryngology Head and Neck Surgery, Philadelphia
  • Country: United States
  • Journal: Journal of Voice (Elsevier, on behalf of The Voice Foundation)
  • Impact evaluation: The impact score of this journal is approximately 2.4, evaluated against a typical high-end range of 0–60+ for top general medical and science journals, therefore this is a Low impact journal. Within its niche it is mid-ranked.

RapAdmin

Researchers sequenced the genome and DNA methylation pattern of Jonathan, an Aldabra giant tortoise estimated to be 194 years old, and compared his methylation with four other Aldabras aged 5 to about 90. Jonathan shows the usual marks of epigenetic aging: genome-wide loss of methylation and rising disorder in his methylation pattern. The exception is a set of 272 gene promoters where his pattern is as orderly as a juvenile’s, and that set is rich in mitochondrial, RNA-processing and DNA-repair genes. The authors propose that protecting these promoters from epigenetic noise helps explain his survival.

Jonathan, an Aldabra giant tortoise living on the South Atlantic island of St Helena, is thought to be 194 years old. That makes him the oldest known land animal and roughly a century past the usual upper limit for his species. A team led by the Kallel Foundation in Nashville has now read both his genome and his methylome, the pattern of chemical tags on DNA that helps decide which genes are switched on.

The headline result is less flattering than the tortoise’s reputation suggests. Jonathan has not escaped epigenetic aging. Compared with a 5-year-old juvenile, his DNA has lost methylation across most of the genome, and about 91 percent of the regions that differ between the two animals carry fewer tags in Jonathan. Genes that guide embryonic development have gained tags instead. Both changes are textbook signs of aging in mammals, humans included.

The researchers also measured methylation entropy, a score of how disordered the tagging pattern has become. Tidy patterns are a feature of young cells. Disorder accumulates over time and, when it reaches the control regions of genes known as promoters, it is linked to erratic gene activity. Across five tortoises aged 5 to 194, whole-genome entropy rose in step with age, and Jonathan sat at the top.

The interesting part is the exception. In 272 gene promoters, Jonathan’s entropy was as low as that of the two youngest animals, while two tortoises of about 90 showed clear disorder. That set of 272 was unusually rich in genes that build and run mitochondria, the cell’s power plants, including parts of the respiratory chain and the scaffolding that shapes the inner mitochondrial membrane. Genes for RNA processing and DNA repair also featured.

From this the authors sketch a model: orderly promoters keep mitochondrial genes firing steadily, a steady energy supply pays for DNA repair, and good repair in turn keeps those promoters orderly. A similar promoter pattern has been reported in long-lived Chinese people, which gives the idea some support from a second species.

The genome itself yielded a long list of candidates. Jonathan carries 770 genes flagged as positively selected and 287 genes with protein-changing variants not seen in the other tortoises examined, many in DNA repair, telomere maintenance and insulin signaling. Like other giant tortoises, he has a duplicated copy of LAMTOR4, a gene in the mTOR growth pathway that rapamycin targets.

The caveats are large. This is one exceptional animal compared with four others, using cheek swabs because St Helena officials would not allow a blood draw. No one measured gene activity, mitochondrial performance or anything else that would show the tidy promoters matter. The 272 genes were selected precisely because they fit the pattern the authors were looking for, and only about a tenth of the tortoise’s promoters could be read at all. The authors acknowledge their data cannot establish cause.

What the study offers is a hypothesis worth testing in other long-lived animals: that surviving to an extreme age may depend less on stopping the epigenetic clock than on protecting a small set of genes from its noise.

Insights

There is nothing in this paper you can take, eat or do. What it does offer is a sense of scale and a direction. Jonathan’s 194 years are about 2.1 times the estimated upper limit for his species (93.7 years) and 2.4 times the mean (80.5 years). The human equivalent would be someone living well past 200. Yet his overall epigenetic disorder still rose with age, so extreme survival did not require a stopped clock.

The one distinctive signal covers 272 of 2,895 readable gene promoters, or 9.4 percent. Of those, 35 (13 percent) are mitochondrial. In that subset, the two tortoises of about 90 showed roughly three to four times Jonathan’s entropy (values read from the figure). The subset was chosen to show exactly that contrast, so the gap is inflated.

The practical reading is modest. The result adds weak, indirect support to the view that preserving mitochondrial function matters in late life. The interventions with human evidence for that remain the familiar ones, chiefly regular aerobic and resistance exercise. This paper does not test them and does not strengthen the case for any supplement.

Context/Source

  • Open Access Paper: Epigenetic insights into extreme longevity in the world’s oldest terrestrial animal, Jonathan
  • Lead institutions: Kallel Foundation (Nashville), Igenbio Inc. (Chicago) and Vanderbilt University Medical Center, with collaborators at UCLA, Harvard Medical School, University of Minnesota, Technical University of Munich, University of Cambridge, University of Copenhagen and the St Helena Government
  • Country: USA (lead), with Germany, UK, Denmark and St Helena
  • Journal: Science Advances, published 7 October 2026
  • Impact evaluation: The impact score of this journal is 13.9 (Journal Impact Factor, 2025 data year, released June 2026), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

A Chinese team built a single-cell “aging clock” from three published human skin datasets and found that the small blood vessels of the skin carry the strongest age signal. They propose that, under chronic inflammation, vessel-lining endothelial cells drift toward a pericyte-like, senescent state marked by the motor protein MYO1B and controlled by the transcription factor ETS1. A computer screen of a drug library flagged the SGLT2 inhibitor ipragliflozin as an ETS1 binder. The drug lowered MYO1B and senescence markers in a cultured endothelial cell line and partially restored epidermal thickness in young rats given D-galactose to mimic aging.

Skin aging is usually told as a story about collagen, sunlight and fibroblasts. This paper argues that the plumbing matters more than we thought.

The researchers pooled three public single-cell RNA datasets of human skin and trained a machine-learning model to guess a donor’s age from gene activity in each cell type. Across 18 donors, predicted age tracked real age reasonably well. The interesting part was where the signal came from. Blood vessel endothelial cells, lymphatic endothelial cells and pericytes, the support cells that wrap around capillaries, were the cell types whose gene activity most consistently tracked age.

Within the pericytes, one subgroup was more common in older donors and carried high levels of MYO1B, a motor protein tied to the cell’s internal skeleton. When the team lined up endothelial cells and these pericytes computationally, they formed a continuous gradient rather than two separate islands. The authors read this as endothelial cells slowly converting into pericyte-like cells with age, a process they call endothelial-to-pericyte transition, or EndoPT.

To test the idea, they bathed a human endothelial cell line in two inflammatory signals, TGF-beta1 and IL-1beta, for a week. The cells lost an endothelial marker, gained pericyte markers including MYO1B, and stained positive for senescence. Silencing the transcription factor ETS1 cut MYO1B expression by roughly 70 percent and reduced senescence staining, and ETS1 was found sitting on the MYO1B gene’s promoter. That gives a plausible chain: inflammation switches on ETS1, ETS1 switches on MYO1B, and the cell shifts identity and senesces.

Then comes the leap. The team docked more than 4,000 drugs against a predicted structure of ETS1. Ipragliflozin, a diabetes drug sold in Japan, ranked third. A binding assay showed the drug sticking to purified ETS1 in a concentration-dependent way, and in cells it lowered MYO1B and two senescence genes. In rats given D-galactose for eight weeks, a standard chemical shortcut for mimicking aging, daily ipragliflozin left the epidermis about 50 percent thicker than in untreated D-galactose rats, though still far thinner than in healthy animals.

The big idea is worth taking seriously: skin aging may be driven partly by a deteriorating vascular niche, and that niche may be druggable. Independent work already links SGLT2 inhibitors to senescent-cell clearance and vascular protection.

But the gap between the idea and the proof is wide. The human evidence comes from 18 donors in the clock and 15 tissue samples whose body sites differ between the young and old groups. The cell identity shift is inferred from snapshots, not tracked in living tissue. The rats were juveniles, all male, six per group, and the study never checked whether the drug’s known whole-body effects on glucose and metabolism explain the skin result. The claim that ipragliflozin works by binding ETS1, rather than through its ordinary pharmacology, rests on computer modeling and one binding experiment with no reported affinity.

Insights

To put the headline result in real-world terms: D-galactose thinned rat epidermis from about 14 micrometers to about 5 micrometers. Ipragliflozin brought it back to about 8 micrometers. That is a gain of roughly 2.6 micrometers, or about 30 percent of the lost thickness recovered. Treated skin was still around 43 percent thinner than healthy skin. The standardized effect size (Cohen’s d) works out to about 1.4, which is “large” on paper, meaning a randomly picked treated rat would have thicker epidermis than a randomly picked untreated one about 85 percent of the time. With only six rats per group, though, the plausible range for that effect runs from trivial to enormous. All of these figures are my estimates read from the paper’s bar chart, since the authors give no numbers in the text.

The rat dose translates to roughly 110 mg per day for a 70 kg adult, about double the standard 50 mg clinical dose.

The practical takeaway is modest: vascular health and chronic inflammation are reasonable things to care about for skin aging, and people already on an SGLT2 inhibitor for medical reasons have one more speculative reason to consider.

Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical and commonly sold under the brand name Suglat, is approved and commercialized in Japan, South Korea, Russia, Taiwan and China. Ipragliflozin is NOT available in India.

Context and Source

  • Open Access Paper: Multimodal profiling uncovers an aging-associated ETS1-MYO1B vascular niche responsive to ipragliflozin
  • Institutions: Department of Dermatology, Shengjing Hospital, China Medical University, Shenyang (lead); and others.
  • Country: China
  • Journal: Frontiers in Cell and Developmental Biology, published 25 September 2026
  • Impact evaluation: The impact score of this journal is 5.3 (Journal Impact Factor; CiteScore 9.9), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

This study investigates the evolutionary adaptations of the FOXO gene family across 137 mammalian species, identifying unique structural mutations in long-lived mammals such as the bowhead whale. By overexpressing bowhead whale FOXO3 and FOXO4 variants in human HeLa cancer cells, researchers demonstrated that these specific proteins predominantly localize to the nucleus and significantly suppress tumor proliferation, migration, and invasion compared to their mouse counterparts. The findings indicate that evolutionary modifications in FOXO proteins enhance their transcriptional activity and tumor-suppressive functions, contributing to the extreme longevity and cancer resistance observed in certain mammalian lineages.

A central question in aging research is why large, long-lived animals do not invariably die of cancer, a phenomenon known as Peto’s Paradox. This paper targets the FOXO family of transcription factors, well-known nodes in longevity and stress resistance pathways, to determine if evolutionary changes in these genes explain the extreme lifespans of species like the 211-year-old bowhead whale.

The research team analyzed FOXO1, FOXO3, FOXO4, and FOXO6 across 137 mammals. They identified 18 positively selected mutation sites unique to long-lived species, suggesting an adaptive evolutionary pressure on these specific genetic sequences. To move beyond computational correlation, the researchers engineered human cervical cancer cells (HeLa) to overexpress either the bowhead whale versions of FOXO3 and FOXO4 or the standard short-lived mouse versions.

The physiological differences were distinct. Whale FOXO proteins naturally migrated into the cell nucleus, the command center where transcription factors must reside to be active. In contrast, mouse FOXO proteins remained largely trapped in the cytosol. Once in the nucleus, the whale FOXO3 protein aggressively upended the cancer cell’s survival programming. It formed a strong bond with STAT1, a known tumor suppressor. It subsequently increased the expression of PTEN (a major inhibitor of cell growth pathways) and FasL (a trigger for programmed cell death), while shutting down BCL6, an oncogene that normally protects cancer cells from dying. Furthermore, it upregulated SOD2, an enzyme that neutralizes mitochondrial oxidative stress.

The clinical implication is that longevity is not just governed by the presence or basic expression levels of FOXO genes, but by structural protein modifications that dictate their cellular localization and binding affinity. These evolutionary tweaks ensure the proteins remain highly active and situated in the nucleus, constantly surveying and suppressing oncogenic activity and oxidative damage.

Actionable Insights

The practical application of this research lies in mimicking the effects of the bowhead whale’s hyper-active FOXO variants. While human gene editing for these specific traits is not currently viable, individuals can target the downstream pathways identified in this paper to improve healthspan. The whale FOXO3 variant successfully upregulates PTEN and SOD2. Individuals can stimulate these same pathways via lifestyle interventions known to drive human FOXO3 into the nucleus, such as intermittent fasting, AMP-activated protein kinase (AMPK) activation, and hormetic stressors like cold exposure and hypoxia conditioning.

The magnitude of the benefit observed when these pathways are optimally activated is substantial. In the human cell models, replacing standard mammalian FOXO3 with the whale variant reduced cancer cell proliferation by approximately 53 percent relative to the mouse baseline (dropping from 32 percent to 15 percent EdU positive cells). It also reduced tumor cell invasion by nearly 60 percent (dropping from roughly 500 to 200 invading cells). By focusing on interventions that upregulate SOD2 for mitochondrial defense and PTEN for cell cycle regulation, health optimization strategies can replicate the mechanistic advantages of these evolutionary adaptations.

Context/Source

RapAdmin

A company-run, 12-week, double-blind trial in 47 women with moderate-to-severe facial photoaging tested a serum containing RLX-201, described as a selective mTORC1 inhibitor, against a vehicle. A blinded dermatologist graded firmness 21% better than baseline in the active group versus roughly 0% for vehicle, and radiance and texture gains were about twice those of vehicle. The instrument-measured difference was much smaller, and the headline “91% mTORC1 suppression” comes from lab-grown skin, not from the participants.

For a decade, longevity researchers have wondered whether the anti-aging effects of rapamycin could be captured in skin without swallowing an immunosuppressant. A 2019 Drexel University trial hinted that they could, showing that topical rapamycin lowered a senescence marker in the hands of older adults. Now a New York company, Rapalogix Health, reports the first controlled human trial of its own compound, RLX-201, which it describes as blocking only mTORC1, the half of the mTOR system tied to growth and suppressed cellular cleanup.

The trial enrolled 47 women aged 35 to 65 at a single North Carolina site. About two-thirds applied the RLX-201 serum twice daily and the rest applied a matching vehicle. Everyone also used the same SPF 30 moisturizer in the morning and a plain moisturizer at night. A dermatologist who did not know who got what scored each face at weeks 2, 4, 8 and 12.

On the primary measure, firmness, the active group improved 21% from baseline by week 12, while the vehicle group barely moved. Cheek wrinkles improved 21% against about 6%. Radiance, luminosity and texture improved 38 to 40%, against 15 to 18% for vehicle. No side effects were recorded in either group.

Those are respectable numbers for a cosmetic, but three things temper them. First, the vehicle group’s gains show how much a consistent sunscreen and moisturizer routine achieves alone: close to half of the headline radiance and texture improvement. Second, the only objective instrument in the trial, a suction device measuring skin mechanics, showed a far narrower gap. At week 12 the active group had changed 13% and the vehicle group 7%, and the paper’s own chart does not mark that difference as statistically significant, although the text says it was. The gap was widest at week 8 and shrank afterward, which sits awkwardly with the authors’ story of steadily accumulating structural repair.

There are disclosure problems. Three of the five authors work for Rapalogix, the company holds the copyright, and the serum is already on sale, yet the paper declares no conflicts of interest. The compound’s structure and concentration are not given.

The big idea is plausible and worth pursuing. Skin is the one human tissue where a longevity drug’s effect can be watched and biopsied directly. This paper shows a serum that outperformed its base on a dermatologist’s scorecard.

Actionable Insights

What the numbers mean in practice:

  • The firmness gain was 21% of baseline on a 0 to 4 grading scale. The paper does not report baseline scores, but for a typical moderate score that is roughly half a grade or less: visible to a trained eye, modest in a mirror.
  • For radiance and texture, the active serum delivered about 22 to 24 percentage points more improvement than vehicle (roughly 39% versus 16%). Sunscreen plus moisturizer alone produced the first 15 to 18 points.
  • On the instrument reading, the advantage was 6 percentage points (13% versus 7%), and this was not clearly distinguishable from chance at week 12.
  • The paper gives no standard deviations, so a proper standardized effect size cannot be calculated. Working backward from the sample size, the true benefit could plausibly range from trivial to large.

Take-home messages:

  • Daily SPF and moisturizer are the cheapest proven part of this protocol.
  • There is no comparison with retinoids, which have decades of histological evidence, so this is not grounds to replace them.
  • The 12-week safety data are reassuring but thin.
  • You can buy and try the Rapalogix product at this site: https://www.reqhealth.com

Context and Source

  • Open Access Paper: A Novel TORC1 Inhibitor, RLX-201, Improves Skin Health, Biomechanics, and Extracellular Matrix Integrity in a Double-Blind Clinical Study
  • Institutions: Dermatology Consulting Services (High Point, North Carolina); Rapalogix Health Inc. (New York); Day Dermatology and Aesthetics (New York)
  • Country: USA
  • Journal: Journal of Cosmetic Dermatology (Wiley)
  • Impact evaluation: The impact score of this journal is 2.5, evaluated against a typical high-end range of 0 to 12+ for top dermatology journals (0 to 60+ for top general science), therefore this is a Medium impact journal within its specialty.
  • Commercial context: Rapalogix Health is a spinout from Cambrian Bio, and RLX-201 is its proprietary small molecule. The Re-Q Pro-Longevity Face Serum is reported to have launched in May 2026, which is after the paper was submitted and before it was accepted.

Leitura Relacionada: